52 Week Range
As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Harbin Pharmaceutical Clarifies Media Reports Related To GNC's Restructuring
Harbin Pharmaceutical Swings To H1 Net Loss At 42.3 Million Yuan
Harbin Pharmaceutical Group's Controlling Shareholder To Sell Stake In The Company
HARBIN PHARMACEUTICAL GROUP CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's major products include chemical raw medicines, antibiotics, Chinese medicines, chemical drugs, over-the-counter (OTC) medicines, healthcare products, biological engineering, animal vaccines and animal remedies, including injections, powder injections, oral liquid, tablets and capsules, among others. The Company distributes its products within domestic markets and to overseas markets.
Biotechnology & Drugs
No. 7 Qunli Avenue, Daoli District
Chairman of the Board
Chief Accounting Officer, Director
Deputy General Manager, Director
Deputy General Manager
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
U.S. Senator Marco Rubio, a Republican and a China hawk, asked for a national security review of plans by General Nutrition Centers <GNC.N>, or GNC, to sell itself to Harbin Pharmaceutical Group Co Ltd.
U.S. Senator Marco Rubio, a Republican and a China hawk, asked for a national security review of plans by General Nutrition Centers, or GNC, to sell itself to Harbin Pharmaceutical Group Co Ltd.
* SAYS IT SIGNS AUTHORIZATION AND DISTRIBUTION AGREEMENT WITH ISRAEL'S TEVA PHARMACEUTICAL INDUSTRIES, EXPECTS INVESTMENT OF ABOUT 160 MILLION YUAN Source text in Chinese: https://bit.ly/2PdGwJL Further company coverage: (Reporting by Hong Kong newsroom)
China's state-controlled drugmaker Harbin Pharmaceutical Group Holding Co <600664.SS> will buy an about 40 percent stake in U.S. nutritional supplements retailer GNC Holdings Inc <GNC.N> for $300 million and are in talks for a joint venture in China, the companies said.
* GNC HOLDINGS - ON DEAL TERMINATION UNDER CIRCUMSTANCES, CO WILL PAY FEE OF EITHER $10 MILLION OR $18 MILLION TO HARBIN PHARMACEUTICAL GROUP - SEC FILING Source text: (http://bit.ly/2o4g6KY) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.